New Stock News | Frontera Therapeutics Files for Listing on Hong Kong Stock Exchange

According to the Zhixun Financial APP, Frontera Therapeutics has submitted an application for listing on the main board of the Hong Kong Stock Exchange, with UBS Securities Hong Kong Limited and Haitong International Capital Limited as its joint sponsors. According to the prospectus, Frontera Therapeutics is a clinical-stage gene therapy company focused on innovative therapy research and development, with an international business layout dedicated to providing safe, effective, and affordable gene therapy solutions for patients worldwide. Since its establishment in 2019, the company has been committed to independently developing innovative recombinant adeno-associated virus (rAAV) gene therapy. The company has developed a differentiated pipeline with leading clinical progress, providing the best global potential in its class, especially for ophthalmic and cardiovascular diseases.